inclusion criteria: * adult male or female patient, aged 18 or above. * patient diagnosed with sars-cov-2 infection at screening by using the sponsor-supplied rapid sars-cov-2 diagnostic test or rt-pcr. * patient with conditions meeting all of the following criteria: 1. oxygen saturation ≥ 94% on room air. 2. not requiring supplemental oxygen. * patient who has onset of one or more of the sars-cov-2 infection associated symptoms within 7 days prior to the study drug administration.

inclusion criteria: * adult male or female patient, aged 18 or above. * patient diagnosed with sars-cov-2 infection at screening by using the sponsor-supplied rapid sars-cov-2 diagnostic test or rt-pcr. * patient with conditions meeting all of the following criteria: 1. oxygen saturation ≥ 94% on room air. 2. not requiring supplemental oxygen. * patient who has onset of one or more of the sars-cov-2 infection associated symptoms within 7 days prior to the study drug administration.

inclusion criteria: adult male or female patient, aged 18 or above. patient diagnosed with sars-cov-2 infection at screening by using the sponsor-supplied rapid sars-cov-2 diagnostic test or rt-pcr. patient with conditions meeting all of the following criteria: oxygen saturation ≥ 94% on room air. not requiring supplemental oxygen. patient who has onset of one or more of the sars-cov-2 infection associated symptoms within 7 days prior to the study drug administration.

inclusion criteria: adult male or female patient, aged 18 or above. patient diagnosed with sars-cov-2 infection at screening by using the sponsor-supplied rapid sars-cov-2 diagnostic test or rt-pcr. patient with conditions meeting all of the following criteria: oxygen saturation ≥ 94% on room air. not requiring supplemental oxygen. patient who has onset of one or more of the sars-cov-2 infection associated symptoms within 7 days prior to the study drug administration.